Epithalon — Epitalon, synthetic pineal tetrapeptide longevity candidate
Synthetic 4-aa Ala-Glu-Asp-Gly tetrapeptide analog of pineal epithalamin; proposed telomerase activator; primarily Russian/Ukrainian research; limited clinical evidence; sequence AEDG
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
FDA-tracked compound — synthesized for clinical/research use
Fork this card to add platform evidence →
FDA-tracked (reclassified Category 1, Feb 2026) — preclinical/clinical bioassay data exists
Fork this card to add platform evidence →
Snapshot
Class: Synthetic bioregulator tetrapeptide (pineal analog)
Evidence tier: Human clinical evidence
Status: Not approved for any therapeutic indication anywhere. Not a registered prescription medicine in Russia. FDA removed Epitalon from the 503A category 2 compounding list (April 22, 2026; nominations withdrawn) and intends to consult PCAC on July 24, 2026 regarding Epitalon acetate and Epitalon (free base). Sold as a research chemical.
Best-supported effect: Telomerase activation and telomere elongation in cultured human somatic cells (in vitro, Khavinson lab); reduced all-cause mortality in a single unblinded Russian elderly cohort that combined epithalon with thymus-derived peptides — neither claim has been independently replicated outside the originating research program.
Main caveat: Essentially all efficacy claims originate from one research program (Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology). No blinded randomized controlled trial has been completed for any longevity or anti-aging endpoint. The key human cohort study used a combination of epithalon and thymus peptides; effects cannot be attributed to epithalon alone. The telomerase-activation mechanism carries an unresolved theoretical cancer risk: one rat study found increased colon carcinogenesis.
What this is
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide — alanine-glutamate-aspartate-glycine (AEDG) — developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia during the 1980s and 1990s. It was designed as a simplified, chemically defined analog of epithalamin, a crude pineal gland peptide extract that Khavinson's group had studied since the 1970s. The hypothesis was that pineal gland peptides regulate aging-related processes, and that a synthetic version could reproduce those effects in a more controlled form.
Epithalon's primary scientific claim is activation of telomerase — specifically, upregulation of hTERT (telomerase reverse transcriptase) expression in human somatic cells, with associated telomere elongation. The peptide is also described as modulating pineal gland function and melatonin secretion patterns that decline with aging. The research base is extensive within the Khavinson program, spans cell culture, rodent, and some human cohort studies, and has not been independently replicated by Western research groups.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Weak — single-program, combination therapy confound, below modern methodology | One unblinded Russian elderly cohort reporting reduced all-cause mortality, but involving both epithalon and thymus-derived peptides (effect not attributable to epithalon alone); one labeled clinical trial in retinitis pigmentosa; one 12-year study in elderly cardiac patients associated with epithalon; all from the Khavinson or Anisimov St. Petersburg program; not independently replicated in Western settings |
| Animal | Moderate — single-program | Lifespan extension in rodents (mouse, rat) and Drosophila; neuroendocrine and melatonin regulation across aging and lighting models; carcinogenesis studies with mixed signals — one rat study found increased colon carcinogenesis; other carcinogenesis study directions not individually extracted from source |
| In vitro | Moderate — single-lab, limited independent replication | Telomerase activation and telomere elongation in human somatic cells; chromatin remodeling; antioxidant enzyme expression; neurogenesis gene expression stimulation |
| Computational | Not present in source | — |
| Mechanism | Plausible, but in vivo confirmation lacking | hTERT upregulation demonstrated in cultured cells; pineal/melatonin modulation biologically plausible given peptide origin; molecular mechanism by which a four-amino-acid peptide upregulates hTERT is unresolved; in vivo specificity and dose-response unconfirmed independently |
Single-lab concentration note: The overwhelming majority of published evidence — cell culture, animal longevity, and human cohort studies — comes from one Russian research program. published literature explicitly states that as of April 2026, no major Western academic laboratory has independently replicated the core telomerase-activation or human mortality findings.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Telomerase activation and telomere elongation in cultured human somatic cells | Weak / in vitro, single-lab | In vitro | Medium — Khavinson lab origin; limited independent replication; in vitro only; no confirmed in vivo mechanism |
| Reduces all-cause mortality in elderly humans | Weak — combination therapy cohort; single unblinded study; not replicated | Human | Medium — one Russian elderly cohort; combined epithalon + thymus peptides; unblinded by modern standards; not independently replicated; effect not attributable to epithalon alone |
| Modulates melatonin and improves sleep quality | Weak — animal support; uncontrolled community reports only in humans | Animal | Low — plausible via pineal lineage; animal studies support melatonin modulation; no controlled human sleep trial in source |
| Long-term use is safe despite telomerase-activation mechanism | Not established — theoretical cancer risk unresolved; no long-term human safety data | Animal | High confidence in absence — one rat study (Anisimov 2003,) found increased colon carcinogenesis; telomerase is precisely the mechanism cancer cells use for replicative immortality; human long-term safety data essentially absent |
| Reduces biological aging markers in humans | Not established | Human | Medium — scattered Khavinson-program Russian literature; source labels this claim "unverified"; no rigorous Western trial; no consensus on clinically meaningful change in aging biomarkers |
| Holds Russian prescription-medicine approval comparable to Selank or Cerebrolysin | Contradicted | None | High — published literature explicitly states Epithalon does not hold prescription-medicine approval in Russia comparable to other Russian peptides; Russian origin of research program is not equivalent to Russian prescription approval |
Human exposure studied
This section reports exposure used in the human studies identified. It is not a personalized protocol. No blinded RCT for any endpoint has been completed.
| Context | Population | Exposure studied | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| Khavinson human cohort (observational,) | Elderly Russian subjects; age and n not individually extracted in source | Epithalon combined with thymus-derived peptides; intranasal and intramuscular routes described; exact regimen not individually extracted | Multi-year; repeated short courses | All-cause mortality | Unblinded; single center; combination therapy — effect not attributable to epithalon alone; not independently replicated |
| Retinitis pigmentosa clinical trial | Patients with retinitis pigmentosa | Epithalon; route and dose not individually extracted | Not individually extracted | Retina condition improvement | Small Russian trial; methodology details not described in source; single program |
| 12-year study in elderly cardiac patients | Elderly patients with coronary heart disease | Epithalon and/or bioregulator peptides; exact intervention and dose not individually extracted | 12 years | Cardiovascular outcomes (not individually extracted) | Source annotates as "associated with epithalon"; exact intervention composition not confirmed; single program; methodology details not individually extracted |
Safety signals
Human safety data: Very limited. No systematic human safety trial is identified. Per available sources, Epithalon was generally well-tolerated in described Russian clinical use, with injection-site reactions as the most commonly noted adverse event. This per available sources tolerability is from short-course protocols and does not establish long-term safety.
Animal safety signal — colon carcinogenesis: One rat study (Anisimov et al. 2003,) found increased colon carcinogenesis in epithalon-treated animals. Source describes this as an important counterweight that "complicates simplistic telomerase-good narratives." Telomerase activation is the mechanism by which cancer cells achieve replicative immortality; the net effect of exogenous epithalon on cancer risk is unresolved.
Theoretical cancer risk: published literature explicitly frames the telomerase-activation mechanism as "a double-edged sword." Promoting telomerase activity in cells with oncogenic potential is a serious theoretical concern that has not been adequately studied in humans receiving epithalon.
per available sources contraindications: Active or recent-history cancer; pregnancy (no reproductive toxicology of adequate quality); breastfeeding (no transfer or infant safety data); known hypersensitivity to synthetic peptides or formulation components; pediatric use (no safety or developmental data); conditions where promoting cellular proliferation is contraindicated, including certain hematological disorders.
Drug interactions: No controlled clinical pharmacokinetic interactions established. Source describes a theoretical mechanistic concern: if epithalon activates telomerase as claimed, concurrent use with anti-cancer therapy (chemotherapy, radiation) would be mechanistically opposed. No specific CYP-mediated pharmacokinetic interactions are established. Source notes absence of human pharmacovigilance data means novel interactions cannot be ruled out.
Long-term safety: Essentially absent. No systematic long-term human safety study is identified.
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved for any indication | Removed from 503A category 2 compounding list (April 22, 2026; nominations withdrawn). FDA intends to consult PCAC on July 24, 2026 regarding Epitalon acetate and Epitalon (free base). This does not authorize compounding — it remains an unapproved new drug for US compounding purposes pending PCAC action. |
| Russia | Not a registered prescription medicine | published literature explicitly states Epithalon does not hold prescription approval comparable to Cerebrolysin or Selank. Some Khavinson-program bioregulator products are registered as dietary supplements or investigational therapies, not as prescription medicines. |
| EU (EMA) | No marketing authorization | — |
| UK (MHRA) | No authorization | — |
| Canada (Health Canada) | No approval | Investigational only |
| Australia (TGA) | No approval | — |
| WADA | Not specifically listed on Prohibited List (per available sources) | WADA S0 covers substances not approved by any governmental regulatory health authority for human therapeutic use; Epithalon's status under S0 is source-described as potentially applicable. Status is as reported in source; not independently refreshed in this card. |
Clinical trials
No trial registered with FDA-facing registries or conducted under Western GCP standards is identified. Source contains the following human studies from the Russian program:
| Trial / source | Population | Reported intervention | Duration | Endpoint | Status / limitation |
|---|---|---|---|---|---|
| Khavinson cohort | Elderly Russian subjects | Epithalon and thymus-derived peptides; routes and dose not individually extracted; repeated short courses | Multi-year | All-cause mortality | Completed as described; unblinded; not independently replicated; combination therapy — epithalon contribution not isolable |
| Retinitis pigmentosa trial | Patients with retinitis pigmentosa | Epithalon; route and dose not individually extracted | Not extracted | Retina condition improvement | Source labels as clinical trial; detailed methodology not individually extracted |
| Elderly cardiac patients study | Elderly patients with coronary heart disease | Epithalon and/or bioregulators; source annotates as "12-year randomized study associated with epithalon"; details not individually extracted | 12 years | Cardiovascular outcomes | Exact intervention composition, enrollment, and randomization details not individually extracted; single Russian program |
Review articles summarizing these and other Khavinson-program studies (,) are in References only.
Mechanism
Telomerase reverse transcriptase (hTERT) activation: Epithalon is reported to upregulate hTERT expression in cultured human somatic cells, promoting telomere elongation and reactivating telomerase in cells that had reached replicative senescence in vitro. This is the primary mechanistic basis for the compound's longevity framing. The foundational paper is (Khavinson lab, 2003).
Dual biology of telomerase: Telomerase activation is not a one-directional anti-aging effect. Replicative immortality via telomerase is precisely the mechanism by which cancer cells escape senescence. published literature explicitly acknowledges this tension. One rat colon carcinogenesis study found findings that complicate any simple "more telomerase is better" framing. The net in vivo effect on cancer risk has not been resolved.
Pineal and melatonin modulation: As an analog of epithalamin (a pineal extract), epithalon is proposed to influence pineal gland function and normalize melatonin secretion patterns that decline with aging. Animal studies across multiple lighting and aging conditions support effects on melatonin-related signaling.
Additional reported effects: Antioxidant enzyme expression modulation; neuroendocrine regulation; gene expression stimulation during neurogenesis. Largely from the Khavinson program.
Mechanistic status: The molecular basis for how a four-amino-acid peptide upregulates hTERT expression is not resolved at the biochemical level. In vivo dose-specificity and mechanism confirmation independent of the originating lab are absent.
Chemistry
| Property | Value |
|---|---|
| Sequence | Ala-Glu-Asp-Gly (AEDG) |
| Formula | C₁₄H₂₂N₄O₉ |
| Molecular weight | 390.35 Da |
| CAS | 307297-39-8 |
| Length | 4 amino acids |
| Topology | Linear |
| Plasma half-life | Minutes; downstream effects on melatonin signaling described as persisting longer |
| Origin | Synthetic analog of epithalamin; developed at the St. Petersburg Institute of Bioregulation and Gerontology, 1980s–1990s |
| Sequence confidence | Verified (single consistent source; no inter-source conflict) |
Community patterns
This section describes reported off-label use patterns from the available literature. These are not clinically validated protocols.
| Pattern | Evidence quality | Notes |
|---|---|---|
| Research-chemical use for longevity and aging maintenance | Anecdotal / source-aggregated | Community use is described in source as centering on injectable short-course protocols framed as aging maintenance; most consistently reported effects in source are sleep and mood improvements compatible with the pineal/melatonin mechanism — a substantially smaller claim than the telomerase/lifespan framing used in vendor marketing |
| Research-chemical product quality | Quality concern | Source notes research-chemical epithalon products vary substantially in purity, identity, and actual peptide content; independent testing in this market segment has found label-content discrepancies; Khavinson-program clinical preparations are not interchangeable with arbitrary research-chemical products |
Open questions
- Independent Western replication: As of April 2026, no major Western academic laboratory has independently replicated the core telomerase-activation or human mortality findings. This is the primary unresolved question for any longevity claim.
- Blinded controlled trials: No blinded RCT has been completed for any longevity, anti-aging, or telomere-maintenance endpoint. All human evidence in the available literature falls below modern trial-methodology standards.
- Epithalon-specific contribution in cohort data: The key human cohort study combined epithalon with thymus-derived peptides; isolating epithalon's individual contribution to the reported mortality reduction is not possible from the study as described.
- Long-term cancer safety: Given the telomerase-activation mechanism and the rat colon carcinogenesis signal, pharmacovigilance for malignancy outcomes is a critical gap. Short observational windows are insufficient to characterize oncogenic risk.
- Pharmacokinetics in humans: Absorption, distribution, and clearance of exogenous epithalon across administration routes have not been characterized in humans.
- Dose-response: No rigorous dose-finding study exists in humans. The molecular basis for telomerase upregulation at described dose ranges has not been independently confirmed in vivo.
- Research-chemical product equivalence: Whether observations from Khavinson-program preparations generalize to research-chemical products with variable purity and content is unestablished.
▸3-letter notation
▸citationbibtex
@peptide{pep00008,
sequence = {AEDG},
target = {anti-aging},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}